{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:20:54Z","timestamp":1761128454355},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2006,5,31]],"date-time":"2006-05-31T00:00:00Z","timestamp":1149033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s00296-006-0142-3","type":"journal-article","created":{"date-parts":[[2006,5,30]],"date-time":"2006-05-30T10:28:03Z","timestamp":1148984883000},"page":"1078-1083","source":"Crossref","is-referenced-by-count":18,"title":["Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria"],"prefix":"10.1007","volume":"26","author":[{"given":"Eduardo F.","family":"Borba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissiane K.","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romy B.","family":"Christmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille P.","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lio R.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloisa","family":"Bonf\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,5,31]]},"reference":[{"key":"142_CR1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2165\/00003495-199651020-00007","volume":"51","author":"B Fulton","year":"1996","unstructured":"Fulton B, Markham A (1996) Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51:278\u2013298","journal-title":"Drugs"},{"key":"142_CR2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85\u2013118","journal-title":"Immunopharmacology"},{"key":"142_CR3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00041552-199909000-00005","volume":"8","author":"D Jayne","year":"1999","unstructured":"Jayne D (1999) Non-transplant uses for mycophenolate mofetil. Curr Opin Nephrol Hypertens 8:563\u2013567","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"142_CR4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","volume":"60","author":"HW Sollinger","year":"1995","unstructured":"Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225\u2013232","journal-title":"Transplantation"},{"key":"142_CR5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","volume":"345","author":"European Mycophenolate Mofetil Cooperative Study Group","year":"1995","unstructured":"European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321\u20131325","journal-title":"Lancet"},{"key":"142_CR6","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/00007890-199806150-00007","volume":"65","author":"Mathew TH for the Tricontinental Mycophenolate Mofetil Renal Transplatation Study Group","year":"1998","unstructured":"Mathew TH for the Tricontinental Mycophenolate Mofetil Renal Transplatation Study Group (1998) A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Results of three years. Transplantation 65:1450\u20131454","journal-title":"Transplantation"},{"key":"142_CR7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1191\/096120399678840927","volume":"8","author":"M Gaubitz","year":"1999","unstructured":"Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731\u2013736","journal-title":"Lupus"},{"key":"142_CR8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1191\/096120301682430186","volume":"10","author":"EJ Kingdon","year":"2001","unstructured":"Kingdon EJ, McLean AG, Psimenou E et al (2001) The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 10:606\u2013611","journal-title":"Lupus"},{"key":"142_CR9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/rheumatology\/41.8.876","volume":"41","author":"MY Karin","year":"2002","unstructured":"Karin MY, Alba P, Cuadrado MJ, Abbs IC, D\u2019Cruz DP, Khamashta MA, Hughes GRV (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41:876\u2013882","journal-title":"Rheumatology"},{"key":"142_CR10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/ajkd.1998.v31.pm9469489","volume":"31","author":"WA Briggs","year":"1998","unstructured":"Briggs WA, Choi MJ, Scheel PJ Jr (1998) Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31:213\u2013217","journal-title":"Am J Kidney Dis"},{"key":"142_CR11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/ajkd.1998.v32.pm9708620","volume":"32","author":"D Glicklich","year":"1998","unstructured":"Glicklich D, Acharya A (1998) Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 32:318\u2013322","journal-title":"Am J Kidney Dis"},{"key":"142_CR12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1681\/ASN.V104833","volume":"10","author":"MA Dooley","year":"1999","unstructured":"Dooley MA, Cosio FG, Nachman PH et al (1999) Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10:833\u2013839","journal-title":"J Am Soc Nephrol"},{"key":"142_CR13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O\u2019Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971\u2013980","journal-title":"N Engl J Med"},{"issue":"2","key":"142_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1191\/0961203304lu513oa","volume":"13","author":"L Ding","year":"2004","unstructured":"Ding L, Zhao M, Zou W, Liu Y, Wang H (2004) Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus 13(2):113\u2013118","journal-title":"Lupus"},{"key":"142_CR15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"34","author":"TM Chan","year":"2000","unstructured":"Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong\u2013Guangzhou Nephrology Study Group. N Engl J Med 34:1156\u20131162","journal-title":"N Engl J Med"},{"issue":"9","key":"142_CR16","first-page":"S647","volume":"48","author":"EM Ginzler","year":"2003","unstructured":"Ginzler EM, Aranow C, Buyon J, Dooley MA, Merril JT, Petri M, Appel G, Gilkeson G, Wallace D, Weisman M (2003) A multicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (FYC) as induction therapy for severe lupus nephritis (LN) Preliminary results. Arthritis Rheum 48(9):S647","journal-title":"Arthritis Rheum"},{"issue":"1","key":"142_CR17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mjd.2001.114297","volume":"45","author":"S Goyal","year":"2001","unstructured":"Goyal S, Nousari HC (2001) Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45(1):142\u2013144","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"142_CR18","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/archderm.138.12.1616","volume":"138","author":"NM Hanjani","year":"2002","unstructured":"Hanjani NM, Nousari CH (2002) Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 138(12):1616\u20131618","journal-title":"Arch Dermatol"},{"issue":"1","key":"142_CR19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2133.2002.04875.x","volume":"147","author":"S Schanz","year":"2002","unstructured":"Schanz S, Ulmer A, Rassner G, Fierlbeck G (2002) Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147(1):174\u2013178","journal-title":"Br J Dermatol"},{"issue":"8","key":"142_CR20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1191\/0961203303lu417cr","volume":"12","author":"S Vasoo","year":"2003","unstructured":"Vasoo S, Thumboo J, Fong KY (2003) Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 12(8):630\u2013632","journal-title":"Lupus"},{"issue":"8","key":"142_CR21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1191\/0961203303lu419cr","volume":"12","author":"P Alba","year":"2003","unstructured":"Alba P, Karim MY, Hunt BJ (2003) Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 12(8):633\u2013635","journal-title":"Lupus"},{"issue":"7","key":"142_CR22","first-page":"1508","volume":"30","author":"MM Riskalla","year":"2003","unstructured":"Riskalla MM, Somers EC, Fatica RA, McCune WJ (2003) Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 30(7):1508\u20131512","journal-title":"J Rheumatol"},{"issue":"6","key":"142_CR23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/ard.62.6.534","volume":"62","author":"M Bijl","year":"2003","unstructured":"Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG (2003) Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 62(6):534\u2013539","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"142_CR24","first-page":"S586","volume":"48","author":"EM Ginzler","year":"2003","unstructured":"Ginzler EM, Aranow C, Merril JT, Orloff K, Henry D (2003) Toxicity and tolerability of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) in a multicenter trial as induction therapy for lupus nephritis. Arthritis Rheum 48(9):S586\u2013S587","journal-title":"Arthritis Rheum"},{"issue":"4","key":"142_CR25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/art.10417","volume":"47","author":"SL Kolasinski","year":"2002","unstructured":"Kolasinski SL, Chung JB, Albert DA (2002) What do we know about lupus membranous nephropathy? An analytic review. Arthritis Rheum 47(4):450\u2013455","journal-title":"Arthritis Rheum"},{"issue":"4","key":"142_CR26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0270-9295(03)00056-1","volume":"23","author":"JE Balow","year":"2003","unstructured":"Balow JE, Austin HA III (2003) Therapy of membranous nephropathy in systemic lupus erythematosus. Semin Nephrol 23(4):386\u2013391","journal-title":"Semin Nephrol"},{"issue":"1","key":"142_CR27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1191\/0961203305lu2062oa","volume":"14","author":"HA Austin","year":"2005","unstructured":"Austin HA, Illei GG (2005) Membranous lupus nephritis. Lupus 14(1):65\u201371","journal-title":"Lupus"},{"key":"142_CR28","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1681\/ASN.V9122272","volume":"9","author":"MJ Penny","year":"1998","unstructured":"Penny MJ, Boyd RA, Hall M (1998) Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 9:2272\u20132282","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"142_CR29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000085029","volume":"100","author":"C Blume","year":"2005","unstructured":"Blume C, Heise G, Hess A, Waldner C, Grabensee B, Schroer K, Heering P (2005) Different effect of cyclosporine A and mycophenolate mofetil on passive Heymann nephritis in the rat. Nephron Exp Nephrol 100(2):104\u2013112","journal-title":"Nephron Exp Nephrol"},{"key":"142_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1440-1797.2003.00146.x","volume":"8","author":"M Zhao","year":"2003","unstructured":"Zhao M, Chen X, Chen Y, Liu Z, Liu Y, Lu F, Zhang Y, Wang H (2003) Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology 8:105\u2013109","journal-title":"Nephrology"},{"issue":"2","key":"142_CR31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/ajkd.2000.8968","volume":"36","author":"G Miller","year":"2000","unstructured":"Miller G, Zimmerman R III, Radhakrishnan J, Appel G (2000) Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 36(2):250\u2013256","journal-title":"Am J Kidney Dis"},{"key":"142_CR32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/rheumatology\/keh012","volume":"43","author":"PP Kapitsinou","year":"2004","unstructured":"Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM (2004) Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology 43:377\u2013380","journal-title":"Rheumatology"},{"key":"142_CR33","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/j.1523-1755.2004.66030.x","volume":"66","author":"DN Spetie","year":"2004","unstructured":"Spetie DN, Tang Y, Rovin BH, Nadasdy T, Nadasdy G, Pesavento TE, Hebert LA (2004) Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 66:2411\u20132415","journal-title":"Kidney Int"},{"issue":"4","key":"142_CR34","first-page":"175","volume":"39","author":"S Pasquali","year":"1993","unstructured":"Pasquali S, Banfi G, Zucchelli A, Moroni G, Ponticelli C, Zucchelli P (1993) Lupus membranous nephropathy: long-term outcome. Clin Nephrol 39(4):175\u2013182","journal-title":"Clin Nephrol"},{"issue":"2","key":"142_CR35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1681\/ASN.V72299","volume":"7","author":"RP Sloan","year":"1996","unstructured":"Sloan RP, Schwartz MM, Korbet SM, Borok RZ (1996) Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 7(2):299\u2013305","journal-title":"J Am Soc Nephrol"},{"key":"142_CR36","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271\u20131277","journal-title":"Arthritis Rheum"},{"key":"142_CR37","volume-title":"Renal disease: classification and atlas of glomerular disease","author":"J Churg","year":"1982","unstructured":"Churg J, Sobin LH (1982) Renal disease: classification and atlas of glomerular disease. Igaku-Shoin, Tokyo"},{"key":"142_CR38","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630\u2013640","journal-title":"Arthritis Rheum"},{"issue":"9","key":"142_CR39","first-page":"2103","volume":"28","author":"S Buratti","year":"2001","unstructured":"Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A (2001) Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 28(9):2103\u20132108","journal-title":"J Rheumatol"},{"key":"142_CR40","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1097\/01.ASN.0000100145.27188.33","volume":"14","author":"WA Wilmer","year":"2003","unstructured":"Wilmer WA, Rovin BH, Hebert CJ et al (2003) Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 14:3217\u20133232","journal-title":"J Am Soc Nephrol"},{"key":"142_CR41","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M, Gutierrez E, Gonzales E et al (2003) Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 14:1578\u20131583","journal-title":"J Am Soc Nephrol"},{"key":"142_CR42","first-page":"147","volume":"42","author":"J Radhakrishnan","year":"1994","unstructured":"Radhakrishnan J, Kunis CL, D\u2019Agati V, Appel GB (1994) Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 42:147\u2013154","journal-title":"Clin Nephrol"},{"key":"142_CR43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1191\/096120300680198935","volume":"9","author":"D Hallegua","year":"2000","unstructured":"Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR (2000) Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9:241\u2013251","journal-title":"Lupus"},{"key":"142_CR44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1191\/096120399678840837","volume":"8","author":"TM Chan","year":"1999","unstructured":"Chan TM, Li FK, Hao WK et al (1999) Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosupression. Lupus 8:545\u2013551","journal-title":"Lupus"},{"key":"142_CR45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/ajkd.1998.v31.pm9531186","volume":"31","author":"G Moroni","year":"1998","unstructured":"Moroni G, Macario M, Banfi G, Quaglini S, Ponticelli C (1998) Treatment of membranous lupus nephritis. Am J Kidney Dis 31:681\u2013686","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"142_CR46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1191\/0961203305lu2061oa","volume":"14","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Aranow C (2005) Mycophenolate mofetil in lupus nephritis. Lupus 14(1):59\u201364","journal-title":"Lupus"},{"key":"142_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.1998.v31.pm9428445","volume":"31","author":"LJ Reichert","year":"1998","unstructured":"Reichert LJ, Koene RA, Wetzels JF (1998) Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 31:1\u201311","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"142_CR48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1034\/j.1600-6143.2001.001003288.x","volume":"1","author":"MD Denton","year":"2001","unstructured":"Denton MD, Galvanek EG, Singh A, Sayegh MH (2001) Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy. Am J Transplant 1(3):288\u2013292","journal-title":"Am J Transplant"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-006-0142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-006-0142-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-006-0142-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T20:35:15Z","timestamp":1627418115000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-006-0142-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,31]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["142"],"URL":"https:\/\/doi.org\/10.1007\/s00296-006-0142-3","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,31]]}}}